Shawn Singh insider trades: Vistagen Therapeutics (VTGN) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Shawn reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 17, 2022 | VTGN | ↑ Buy | 600,000 | $0.17 | $103K | By The 1997 Singh Family Trust U/R/D 05/ | Aug 18, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Shawn Singh's insider trades
Shawn Singh is President and CEO at Vistagen Therapeutics (VTGN). Since Aug 17, 2022, Shawn has reported 1 open-market purchase worth $103K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (34 filings), option exercises (5 filings), shares returned to the company (4 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VTGN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.